Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma

Seminars in Oncology

Volumn 30, Issue 4 SUPPL. 10, 2003, Pages 32-36

  Manegold, Christian ^a,b  

^a Thoraxklinik   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; EDATREXATE; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; METHOTREXATE; PEMETREXED;

AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; HUMAN; LEUKOPENIA; LUNG FUNCTION TEST; MALIGNANT MESOTHELIOMA; MONOTHERAPY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; VITAMIN SUPPLEMENTATION;

EID: 0041965968     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00283-5     Document Type: Conference Paper

References (10)

1. Kindler HL: Malignant pleural mesothelioma. Curr Treat Options Oncol 1:313-26, 2000
2. Zellos LS, Sugarbaker DJ: Diffuse malignant mesothelioma of the pleural space and its management. Oncology (Huntingt) 16:907-913, 2002 (discussion 916-917, 919-920, 925)
3. Procopio A, Strizzi L, Vianale G, et al: Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. Genes Chromosomes Cancer 29:173-179, 2000
4. Manegold C, Aisner J: Pemetrexed for the diffuse malignant pleural mesothelioma. Semin Oncol 29:30-35, 2002 (suppl 5)
5. Thoedtmann R, Depenbrock H, Dumez H, et al: Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 17: 3009-3016, 1999
6. Calvert H: Folate status and the safety profile of antifolates. Semin Oncol 29:3-7, 2002 (suppl 5)
7. Vogelzang NJ, Rusthoven J, Paoletti P, et al: Phase III single-blinded study of pemetrexed plus cisplatin versus cisplatin alone in chemo-naive patients with malignant pleural mesothelioma. Proc Am Soc Clin Oncol 21:2a, 2002 (abstr 5)
8. Liepa A, Rusthoven J, Denham C, et al: Clinical benefit algorithm for malignant pleural mesothelioma: Results from randomized trial of pemetrexed plus cisplatin versus cisplatin. Ann Oncol 13:129, 2002 (suppl 5) (abstr 475 PD)
9. Shin DM, Scagliotti G, Kindler H, et al: A phase II trial of pemetrexed in malignant pleural mesothelioma (MPM) patients: Clinical outcome, role of vitamin supplementation, respiratory symptoms and lung function. Proc Am Soc Clin Oncol 21:294a, 2002 (abstr 1175)
10. Hughes A, Calvert P, Azzabi A, et al: Phase I clinical and pharmacokinetics study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20:3533-3544, 2002